This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the "astrocyte-neuron lactate shuttle (ANLS)" hypothesis. Mitochondrial pathophysiology in TBI has still been unclear.
Thus, the pharmacological treatment in TBI patient is still challenging. Now we hope this presenting review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI